CLINICAL_TRIALS
trial_result
· 2010-12-10
Clinical Trial Update: A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus [Phase 2, Phase 3]
Summary
A study evaluating rituximab retreatment safety in systemic lupus erythematosus has completed (Phase 2/3).
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Genentech, Inc. | Conditions: Lupus Erythematosus, Systemic | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2010-12-10